What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?

Ryan Phillips; Piet Ost; Phuoc T Tran

doi:10.2217/fon-2017-0337

What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?

Future Oncol. 2017 Oct;13(24):2121-2124. doi: 10.2217/fon-2017-0337. Epub 2017 Oct 11.

Authors

Ryan Phillips¹, Piet Ost², Phuoc T Tran^{1

3}

Affiliations

¹ Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, MD, USA.
² Department of Radiation Oncology & Experimental Cancer Research, Ghent University, Ghent, Belgium.
³ Departments of Oncology & Urology, Johns Hopkins University, MD, USA.

PMID: 29019420
DOI: 10.2217/fon-2017-0337

No abstract available

Keywords: castration-resistant prostate cancer; neoplasm metastasis; neoplasm recurrence; oligometastasis; prostate cancer; stereotactic ablative radiotherapy; stereotactic body radiation therapy.

Publication types

Editorial

MeSH terms

Humans
Male
Neoplasm Metastasis
Neoplasm Staging
Prostatic Neoplasms, Castration-Resistant / mortality
Prostatic Neoplasms, Castration-Resistant / pathology*
Prostatic Neoplasms, Castration-Resistant / radiotherapy*
Radiosurgery* / methods
Treatment Outcome

Grants and funding

R01 CA166348/CA/NCI NIH HHS/United States